AUS
NZ
UK
CA
USA
IND
Highlights
- ACELYRIN will present updated Phase 2 data for lonigutamab in TED treatment.
- Phase 3 LONGITUDE program for TED treatment to be unveiled, focusing on inclusivity.
- Experts from Stanford and University of Colorado to discuss TED’s unmet needs.
ACELYRIN (Nasdaq:SLRN) has announced a virtual investor event scheduled for January 6, 2025, at 4:30 PM ET, where the company will present updated Phase 2 data for its investigational treatment, subcutaneous lonigutamab, in Thyroid Eye Disease (TED). The event is expected to highlight the promising potential of lonigutamab, positioning it as a candidate for best-in-class efficacy and safety in treating TED, a rare and debilitating autoimmune condition affecting the eyes.
The company will also introduce the design of its Phase 3 LONGITUDE program, a pivotal clinical trial initiative developed after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The LONGITUDE program aims to be the most inclusive registrational study in TED to date, addressing the need for comprehensive and diverse participant representation in clinical trials. This inclusivity is expected to enhance the generalizability of results, ensuring that the treatment is effective for a broader range of TED patients.
In addition to presenting the updated data and program design, ACELYRIN’s virtual event will feature clinical insights from leading experts in the field of TED. Experts from the Stanford University School of Medicine and the University of Colorado School of Medicine will provide valuable external perspectives on the current gaps in TED treatment and discuss the unmet medical needs of TED patients. These expert opinions will underscore the significance of lonigutamab as a potential therapeutic breakthrough for TED patients who currently have limited treatment options.
The ongoing development of lonigutamab underscores ACELYRIN’s commitment to addressing the critical challenges in TED, which is characterized by inflammation, tissue expansion, and ocular complications. With no FDA-approved treatments currently targeting TED’s root causes, lonigutamab’s development offers hope for patients suffering from this chronic condition. If successful, lonigutamab could become a transformative treatment, offering both efficacy and safety that is expected to outperform existing therapeutic options.
CEO of ACELYRIN, [Insert Name], expressed optimism about the event and the company’s progress, stating that the updated data and Phase 3 program design represent a major step forward for lonigutamab and TED treatment. He emphasized the importance of collaborating with academic experts to ensure that the clinical trial reflects the real-world challenges faced by TED patients and their healthcare providers.
With the upcoming investor event, ACELYRIN is poised to make a strong case for the future of lonigutamab in TED treatment. The company’s commitment to scientific excellence, innovative program design, and collaboration with leading medical institutions places it at the forefront of efforts to develop new, effective therapies for this underserved patient population.
